Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration
Retrieved on:
Wednesday, January 18, 2023
Health, Infectious Diseases, COVID-19, Research, Science, Pharmaceutical, Biotechnology, Emricasan, Peace and Collaborative Development Network, Immunity, CDCA, Safety, Videophilia (and Other Viral Syndromes), Organization, Immune system, Patient, HIV disease progression rates, Caspase, Commercialization, Pharmaceutical industry, COVID19
Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.
Key Points:
- Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.
- Caspase molecules help build immunity to pathogens, but can also have detrimental effects on the immune system.
- The scientists at Amerimmune had the idea that a stronger and prolonged caspase activity can cause the poor outcomes seen in some patients with COVID-19.
- Histogen Inc. filed for arbitration to terminate the Collaborative Development and Commercialization Agreement (CDCA) between Amerimmune and Histogen Inc.